ClinicalTrials.gg
CompletedNCT04451408Updated Mar 28, 2025

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

A Phase 1 interventional study of LY3372993 and Placebo in Alzheimer Disease and Healthy, sponsored by Eli Lilly and Company. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 19 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.

Enrollment
40th of 95
139 · median 95
Started
2020
with 2 others
Phase 1
34 of 99
6 open now
Registered
75th of 99
by date

Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 40th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2020, is one of 34 in phase 1, and was the 75th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Alzheimer Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.

03

Conditions studied

  • Alzheimer Disease
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(Part A)

  • Gradual and progressive changes in memory function reported by participants or their partners for greater than or equal to (≥) 6 months at screening, and a clinical diagnosis of mild cognitive impairment due to AD, or AD dementia, as determined by the investigator or based upon medical history
  • score ≥16
  • Have clinical laboratory test results within normal reference range or results with acceptable deviations that are judged to be not by the investigator
  • Have a study partner who will provide written to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available through telephone at designated times

(Part B)

  • overtly healthy males or females
  • have a of 18.0 to 32.0 kg/m2, inclusive
  • To qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion criteria

Exclusion Criteria:

(Part A)

  • Have history or presence of uncontrolled asthma, significant disease, hereditary angioedema, or known history of common variable immune deficiency
  • to positron emission tomography (PET)
  • Have a history or presence of serious or unstable illnesses including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's of less than (\<)24 months
  • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
  • Have had significant medical history of dizziness, syncope, or vasovagal attacks within the past 3 years
  • Contraindication to magnetic resonance imaging (MRI), including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker

(Part B)

  • have a family history of early onset AD (AD diagnosed prior to 65 years of age)
  • have used or intend to use over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.
  • have a history or presence of significant psychiatric disorders
  • have an abnormal blood pressure and/or pulse rate as determined by the investigator, or a pre-existing history of hypertension
  • any or brain MRI abnormalities
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    LY3372993 (Part A)

    LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC).

    Drug: LY3372993

  • Experimental
    LY3372993 (Part B)

    LY3372993 administered as single dose IV or SC.

    Drug: LY3372993

  • Placebo comparator
    Placebo (Part A)

    Placebo administered as multiple doses IV or SC.

    Drug: Placebo

  • Placebo comparator
    Placebo (Part B)

    Placebo administered as single dose IV or SC.

    Drug: Placebo

Interventions

  • Administered IV or SC.

  • DrugPlacebo

    Administered IV or SC.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 61 (part A) and Week 13 (Part B)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3372993

    PK: Cmax of LY3372993

    Time frame: Day 1 Predose through Week 61 (part A) and Week 13 (Part B)

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3372993

    PK: AUC of LY3372993

    Time frame: Day 1 Predose through Week 61 (part A) and Week 13 (Part B)

  3. Pharmacodynamics (PD): Change from Baseline in Cerebral Amyloid Plaque Level (Part A only)

    PD: Cerebral amyloid plaque level measured using florbetapir positron emission tomography

    Time frame: Baseline and Week 61 (part A)

07

Study locations

13 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Accel Research Sites- Clinical Research Unit
    DeLand, Florida 32720, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • IMIC, Inc.
    Miami, Florida 33176, United States
  • Ppd Development
    Orlando, Florida 32806-1041, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Charter Research
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US, Inc.
    The Villages, Florida 32162, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
  • Oita University Hospital
    Yufu, Oita 879-5503, Japan
  • The University of Tokyo Hospital
    Bunkyo-ku, Tokyo 113-8655, Japan
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, Tokyo 162-0053, Japan
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2024, 52 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 52 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jun 30, 2020
StartActual
Jul 7, 2020
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451408
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 7, 2020
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Mar 28, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remternetug

Start the discussion